

Kristian Reckzeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/665748/publications.pdf>

Version: 2024-02-01

9

papers

110

citations

1478505

6

h-index

1588992

8

g-index

9

all docs

9

docs citations

9

times ranked

192

citing authors

#	ARTICLE	IF	CITATIONS
1	TET2 deficiency cooperates with CBFβ-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event. British Journal of Haematology, 2022, , .	2.5	4
2	Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML. Cancer Research, 2022, 82, 2141-2155.	0.9	8
3	Inhibition of Oxidized Nucleotide Sanitation By TH1579 and Conventional Chemotherapy Cooperatively Enhance Oxidative DNA Damage and Survival in AML. Molecular Cancer Therapeutics, 2022, 21, 703-714.	4.1	3
4	Transcription factor-driven coordination of cell cycle exit and lineage-specification in vivo during granulocytic differentiation. Nature Communications, 2022, 13, .	12.8	16
5	Targeted inhibition of cooperative mutation- and therapy-induced AKT activation in AML effectively enhances response to chemotherapy. Leukemia, 2021, 35, 2030-2042.	7.2	14
6	Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance. , 2021, 4, 984-995.		1
7	Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Science Advances, 2019, 5, eaaw4304.	10.3	28
8	Human adult HSCs can be discriminated from lineage-committed HPCs by the expression of endomucin. Blood Advances, 2018, 2, 1628-1632.	5.2	10
9	The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers. Oncotarget, 2017, 8, 44605-44624.	1.8	26